CHMP recommends EU approval of Roche ’s Gazyvaro for people with previously untreated advanced follicular lymphoma

Roche announced today that the EU Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for Gazyvaro ® (obinutuzumab) in combination with chemotherapy, followed by Gazyvaro maintenance in people achieving a response, as a new treatment option for previously untreated advanced follicular lymphoma.
Source: Roche Media News - Category: Pharmaceuticals Source Type: news